M&A | Partnerships

Link Health will have global rights for development, manufacturing and commercialization of ALLOB allogeneic bone cell therapy.

Biologics4Life is developing a injectable synthetic bone graft materials, complementing Graftys' resorbable calcium phosphate cement.

The combined company will operate as a pure-play regenerative medicine and orthopedics company, serving hospital, ASC and office care settings.

Vilex will market and distribute Royal Biologics' portfolio of Autologous and Live Cellular therapies for lower extremity orthopedic procedures.

The merger will create a company positioned with products and specialized salesforces serving hospital, ambulatory surgical center and office care settings.

Exactech's Optecure demineralized bone matrix will complement RTI Surgical's portfolio of bone graft substitutes.

The group purchasing agreement for Synthetic Implantable Products allows Premier members to access pricing and terms for CERAMENT bone void filler.

Kuros has signed a sales agency agreement with various entities, covering the Netherlands, Switzerland, Austria and Finland.

The transaction includes GUIDOR bone graft substitutes known as easy-graft and calc-i-oss, and builds on the company's strategy to expand its technologies.

Over 25,000 of Theracell's licensed demineralized bone fiber products have been delivered by the company's licensee partners.